|
Clinical Trial Update
|
27 June 2023 at 10:20am
|
|
Life Sciences Investor Forum Presentation
|
23 June 2023 at 11:10am
|
|
Starpharma to present at Life Sciences Investor Forum
|
22 June 2023 at 1:10pm
|
|
AZD0466 Clinical Data Presented by AstraZeneca EHA Congress
|
14 June 2023 at 11:00am
|
|
Starpharma CEO to retire in 2024
|
9 June 2023 at 9:55am
|
|
VIRALEZE Nasal Spray Approved in Malaysia
|
5 June 2023 at 10:10am
|
|
Application for quotation of securities - SPL
|
5 May 2023 at 5:25pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 9:59am
|
|
HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
|
26 April 2023 at 10:40am
|
|
AZD0466 active in small cell lung cancer patient models
|
20 April 2023 at 9:45am
|
|
DEP cabazitaxel Ph 2 trial completes enrolment & treatment
|
17 April 2023 at 10:45am
|
|
Commencement of CFO and Company Secretary
|
3 April 2023 at 9:25am
|
|
Starpharma presents at ASX Small and Mid-Cap Conference
|
22 March 2023 at 10:45am
|
|
Application for quotation of securities - SPL
|
17 March 2023 at 4:55pm
|
|
CFO and Company Secretary Appointment
|
3 March 2023 at 10:00am
|
|
Interim Report and Half-Year Financial Results
|
28 February 2023 at 9:50am
|
|
Dr Russell Basser appointed as director and Appendix 3X
|
20 February 2023 at 2:45pm
|
|
Change in substantial holding
|
10 February 2023 at 5:40pm
|
|
Change in substantial holding
|
10 February 2023 at 8:50am
|
|
Application for quotation of securities - SPL
|
1 February 2023 at 2:59pm
|
|
Appointment of Company Secretary
|
1 February 2023 at 10:05am
|
|
Dr Russell Basser appointed as non-executive director
|
31 January 2023 at 11:40am
|
|
Quarterly Activities Report & Appendix 4C
|
30 January 2023 at 10:20am
|
|
Response to ASX Query Letters
|
12 January 2023 at 12:20pm
|
|
Starpharma receives $7.1M R&D tax incentive refund
|
23 December 2022 at 8:50am
|
|
Resignation of CFO / Company Secretary
|
21 December 2022 at 12:40pm
|
|
VIRALEZE Nasal Spray Registered in Indonesia
|
14 December 2022 at 11:25am
|
|
Positive AZD0466 clinical data presented by AstraZeneca
|
13 December 2022 at 11:30am
|
|
VIRALEZE Post-Market Clinical Study in COVID-19 Patients
|
8 December 2022 at 10:05am
|
|
Change in Director's Interest Notice - J Fairley
|
5 December 2022 at 4:00pm
|
|
Notification regarding unquoted securities - SPL
|
5 December 2022 at 3:55pm
|
|
Retirement of non-executive Director
|
30 November 2022 at 3:00pm
|
|
AGM Results
|
29 November 2022 at 5:05pm
|
|
AGM Chairman address and CEO presentation
|
29 November 2022 at 1:20pm
|
|
VIRALEZE launched in Hong Kong and Macau
|
21 November 2022 at 10:20am
|
|
Starpharma to present at Bell Potter Healthcare Conference
|
8 November 2022 at 11:15am
|
|
Change in Director's Interest Notice - R Thomas
|
31 October 2022 at 1:10pm
|
|
Change in Director's Interest Notice - J Fairley
|
31 October 2022 at 1:05pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 October 2022 at 2:45pm
|
|
Application for quotation of securities - SPL
|
27 October 2022 at 3:10pm
|
|
Notification regarding unquoted securities - SPL
|
27 October 2022 at 3:10pm
|
|
Quarterly Activities Report & Appendix 4C
|
26 October 2022 at 10:20am
|
|
VIRALEZE distribution agreement for Hong Kong and Macau
|
21 October 2022 at 10:10am
|
|
Change in substantial holding
|
21 October 2022 at 8:40am
|
|
Change in Director's Interest Notice - J Fairley
|
7 October 2022 at 1:40pm
|
|
Notification of cessation of securities - SPL
|
7 October 2022 at 1:35pm
|
|
Board Renewal
|
5 October 2022 at 1:40pm
|
|
2022 Annual General Meeting Date
|
30 September 2022 at 2:55pm
|
|
Starpharma to present at Life Sciences Investor Forum
|
15 September 2022 at 4:45pm
|
|
Change in substantial holding
|
12 September 2022 at 5:00pm
|
Starpharma Holdings